ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Break Above 50-Day Moving Average – Should You Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report)’s share price passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $113.47 and traded as high as $118.03. ProShares Ultra Nasdaq Biotechnology shares last traded at $117.7660, with a volume of 5,877 shares traded.

ProShares Ultra Nasdaq Biotechnology Trading Up 4.5%

The firm has a market capitalization of $101.28 million, a price-to-earnings ratio of 20.68 and a beta of 1.25. The company has a fifty day moving average price of $113.47 and a 200-day moving average price of $95.82.

ProShares Ultra Nasdaq Biotechnology’s stock is scheduled to split on Thursday, November 19th. The 2-1 split was recently announced. The newly created shares will be distributed to shareholders after the market closes on Wednesday, November 18th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Investment Advisors LLC purchased a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the third quarter worth about $658,000. Toth Financial Advisory Corp purchased a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the third quarter valued at approximately $118,000. Finally, Kaizen Financial Strategies grew its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 4.7% during the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock worth $483,000 after acquiring an additional 250 shares during the period.

About ProShares Ultra Nasdaq Biotechnology

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.

See Also

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.